Bright Minds Biosciences (NASDAQ:DRUG) shares are under the spotlight following the announcement of "positive and significant" topline results from its Phase 2 BREAKTHROUGH study.
The trial evaluated BMB-101, a first-in-class selective 5-HT2C biased agonist, in patients suffering from drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE).
The study, which exceeded its enrollment target with 24 adult patients, demonstrated that BMB-101 could provide a significant therapeutic benefit for those who have failed an average of 4 to 10 previous anti-seizure treatments.
In the Absence Seizure cohort, patients saw a 73.1% median reduction in seizures lasting 3 seconds or longer.
Results were equally compelling in the DEE cohort, which included patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome, showing a 63.3% median reduction in major motor seizures.
A standout discovery from the trial was BMB-101’s impact on sleep architecture.
While total sleep time remained stable, treated patients experienced a 90% increase in REM sleep.
In the context of epilepsy, this is considered a significant clinical secondary benefit, as REM sleep is known to have a natural "anti-epileptic" effect due to cortical desynchronization, which helps prevent the propagation of seizure activity.
With $913 million in capital (from previous updates) and a successful Proof-of-Concept, Bright Minds is now moving toward global registrational trials and a new study in Prader-Willi Syndrome starting in Q1 2026.